Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus palbociclib and fulvestrant vs placebo plus palbociclib and fulvestrant in HR+ HER2- advanced breast cancer
jRCT2080224945Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ipatasertib + palbociclib + fulvestrant with Placebo + palbociclib + fulvestrant (2 arms). Started Nov 2019; status: completed.
02
Drugs
ipatasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224945.